搜索优化
English
搜索
图片
Copilot
视频
地图
资讯
购物
更多
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
JD Supra
4 天
A New Generation of SPACs Leads the Way Into 2025
After a two-and-a-half-year lull in SPAC activity, the second half of 2024 brought glimmers of sunshine to the otherwise ...
4 天
IPO Revival Likely to Continue into Mid-2025
According to Nasdaq’s data, the U.S. saw 179 non-SPAC IPOs in 2024 – the most since 2021, and a 40% increase over 2023 (127). By value raised (ex SPACs), it was an even better year, with value raised ...
Finbold | Finance in Bold
4 天
Why Robinhood (HOOD) stock is soaring
Robinhood (NASDAQ: HOOD) stock is back to a price last seen in September 2021, soaring above $45.81 in an impressive comeback ...
5 天
on MSN
Guzman Y Gomez shares: Overvalued or still a buy?
Is the GYG valuation too spicy? The post Guzman Y Gomez shares: Overvalued or still a buy? appeared first on The Motley Fool ...
6 天
Impinj Is Taking Off, But The Market Has Overestimated Its Profit Path
Impinj has shown impressive revenue growth post-2020 but has faced persistent operating losses since its 2016 IPO. The ...
Stratechery
6 天
AI’s Uneven Arrival
AGI, which is AI that can complete tasks; it may take longer for most companies to adopt them than you might think — just look at digital advertising.
来自MSN
10 天
Despite Struggles, Palantir Secures Spot Among 25 'Perfect' Stocks
Palantir, Netflix and three high-flying "apps" maintain their spot among 25 highly rated stocks in the top-ranked industries.
11 天
METCZ: An 8.375% Senior Note IPO From Ramaco Resources
Ramaco Resources, Inc.'s new 8.375% Senior Notes due 2029, METCZ, have increased the company's debt-to-equity ratio from 0.25 ...
tbsnews
12 天
Regulator charts new course to revive IPO market amid capital crunch
In November, the BSEC requested the finance ministry and the National Board of Revenue for a five year tax holiday to ...
FierceBiotech
13 天
Maze Therapeutics looks for IPO lodestar to guide kidney disease assets through clinical trials
Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈